A Randomized Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR RCT): Primary Efficacy and Safety Findings.

John K BotsonKenneth SaagJeff PetersonNaval ParikhStephen OngDan LaKaron LoCiceroKatie ObermeyerYan XinJason ChamberlainBrian LaMoreauxSupra VermaStephen SainatiSuneet GrewalAmar MajjhooJohn R P TesserMichael E Weinblatt

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2022)

MTX co-therapy markedly increased pegloticase response rate over PBO (71.0% vs. 38.5%) during Month-6 with no new safety signals. These findings verify higher treatment response rate, lower IR incidence, and lower immunogenicity when pegloticase is co-administered with MTX.

Keyphrases

risk factors
high dose
uric acid
clinical trial
metabolic syndrome
double blind
low dose